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Abstract
OBJECTIVE: During the development of cosmetic formulations,
in vitro and in vivo methods are essential tools used to reliably
assess the skin irritation potential of a product or ingredient. Epicu-
taneous patch testing (single and/or multiple application protocols)
has long been used as an initial in vivo method to screen for possi-
ble skin irritation properties of a substance or formulation. To con-
firm the mildness and dermatological and/or consumer acceptance
of a product, use tests are often subsequently conducted. A study
was therefore initiated to see how well patch test results correlate
with use tests with respect to irritation elicited by skincare (leave-
on) products.
METHODS/RESULTS: A number of different cosmetic formula-
tions were assessed in both tests. Although the patch test results
did not indicate substantial irritation potentials, immediate-type
reactions (stinging and redness) were observed in some volunteers
which disappeared within approx. 1 h. Although transient, these
reactions suggested that consumer acceptance would probably be
low and the studies were discontinued. Immediate-type reactions
are rare but have been described for some substances used in cos-
metics. These unexpected results were nevertheless intriguing and
prompted the start of a journey to see if patch test protocols could
be modified to assess these reactions. An occlusive short-term patch
test protocol with an application period of 20 min was developed.
Successful identification of the spontaneous reactions became possi-
ble. Furthermore, there was a correlation between the intensity of
reactions observed in the short-term patch test and those observed
in the controlled in-use studies. Short-term patch testing using the
developed protocol can therefore reliably be used as a screening
method, for example in the development and optimization of cos-
metic formulations containing ingredients that could cause
spontaneous reactions, for instance of non-immunological contact
urticaria type.
CONCLUSION: The lessons learned from this studies indicate that
simple modifications of existing test protocols can lead to important
insights into skin reactions. These modifications can then be used
to create further building blocks in the development and optimiza-
tion of test strategies for cosmetic formulations which offer reliable
study designs for possible reactions product developers may
encounter.
Resume
OBJECTIF: Lors du developpement de formulations cosmetiques,
les methodes in vitro et in vivo sont des outils essentiels utilises
pour evaluer de maniere fiable le potentiel d’irritation cutanee d’un
produit ou d’un ingredient. Le test epicutane (protocoles d’applica-
tion uniques et / ou multiples) est utilise depuis longtemps comme
methode initiale in vivo pour depister les eventuelles proprietes d’ir-
ritation cutanee d’une substance ou d’une formulation. Afin de
confirmer la douceur et l’acceptation dermatologique et / ou con-
sommateur d’un produit, des tests d’usage sont souvent effectues
ulterieurement. Une etude a donc ete initiee pour voir dans quelle
mesure les resultats des tests epicutanes correspondent aux tests
d’usage en ce qui concerne l’irritation provoquee par les produits
de soin (sans rincage).
METHODES/RESULTATS: Un certain nombre de formulations
cosmetiques differentes ont ete evaluees dans les deux tests. Bien
que les resultats du test epicutane n’indiquent pas de potentiels
d’irritation substantiels, des reactions de type immediat (picote-
ments et rougeurs) ont ete observees chez certains volontaires. Cel-
les-ci ont disparu en a peu pres 1 heure. Bien que transitoires, ces
reactions de type 5 suggeraient que l’acceptation du consommateur
serait probablement faible et les etudes ont ete interrompues. Les
reactions de type immediat 6 sont rares mais ont ete evoquees en
relation avec certaines substances utilisees en cosmetique. Ces
resultats inattendus etaient neanmoins intrigants et ont incite le
lancement d’un processus pour voir si les protocoles de test epicu-
tane pouvaient être modifies pour evaluer ces reactions. Un proto-
cole de test epicutane a court terme occlusif avec une periode
Correspondence: Nicole Braun, DermaTronnier GmbH & Co. KG,
Institute for Experimental Dermatology at Witten/Herdecke University,
Witten, Germany. Tel +49 2302 2826300; fax: +49 2302 2826326;
e-mail nicole.braun@uni-wh.de
Working group No 1: Safety and Skin Compatibility of the German
Society for Scientific and Applied Cosmetic (DGK)
328 © 2020 The Authors.International Journal of Cosmetic Science published by John Wiley & Sons Ltd
on behalf of Society of Cosmetic Scientists and Societe Francaise de Cosmetologie
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
International Journal of Cosmetic Science, 2020, 42, 328–335 doi: 10.1111/ics.12619
d’application de 20 min a ete developpe, permettant l’identification
reussie des reactions spontanees. Il a ete de plus constate une
correlation entre l’intensite des reactions observees dans le test epi-
cutane a court terme et celles observees dans les test d’usage con-
trôles. Le test epicutane a court terme utilisant le protocole
developpe peut donc être utilise de maniere fiable comme methode
de depistage, par exemple dans le developpement et l’optimisation
de formulations cosmetiques contenant des ingredients qui pour-
raient provoquer des reactions spontanees, par exemple de type
urticaire de contact non immunologique.
CONCLUSION: Les lecons tirees de ces etudes indiquent que de
simples modifications des protocoles de test existants peuvent
reveler des informations importantes sur les reactions cutanees. Ces
modifications peuvent ensuite être utilisees pour creer d’autres
blocs de construction dans le developpement et l’optimisation de
strategies de test pour des formulations cosmetiques qui offrent des
conceptions d’etudes fiables pour les reactions possibles que les
developpeurs de produits peuvent rencontrer.
Introduction
What is a cosmetic? According to EU Cosmetic Regulation (EC) N°
1223/2009 on cosmetic products, a ‘cosmetic product’ means any
substance or mixture intended to be placed in contact with the
external parts of the human body (epidermis, hair system, nails,
lips and external genital organs) or with the teeth and the mucous
membranes of the oral cavity with a view exclusively or mainly to
cleaning them, perfuming them, changing their appearance, pro-
tecting them, keeping them in good condition or correcting body
odours [1]. Similar definitions can be found in other regulatory
frameworks, and these definitions govern products placed on the
market in that region. Regulation (EC) N° 1223/2009 mandates
that cosmetic products put on the market should not be harmful to
human health with Annex 1 §8 specifying that a particular focus
should lie on local toxicity which includes skin irritation.
During the development of cosmetic formulations, in vivo human
test methods are indispensable tools used to assess the skin irrita-
tion potential of a product or ingredient. Epicutaneous patch test-
ing for irritation (ECT; single and/or multiple application protocols)
has long been used as an initial in vivo method to screen for possi-
ble skin irritation properties of a substance or formulation [2,3]. To
confirm the mildness and dermatological and/or consumer accep-
tance of a product, use tests are often subsequently conducted. The
types and protocols of tests that can be conducted are manifold,
and it is necessary that test strategies are suitable for the products
to be tested. A guideline for the assessment of skin compatibility of
cosmetic products in humans is described by Cosmetics Europe [4]
and a comprehensive overview of criteria and test possibilities was
published by the DGK working group: Safety and Skin Compatibil-
ity of the German Society for Scientific and Applied Cosmetic [5].
Epicutaneous patch testing (ECT) remains the gold standard for
skin compatibility testing and focuses on the acute irritation poten-
tial. To this accord, use of the exaggerated conditions of occlusion
and relatively long single exposure times, depending on the proto-
col used generally ranging from 24 to 48 h, are involved. In con-
trast, ‘use tests’ are generally conducted under non-occlusive
(open) conditions with repeated applications which represent the
application procedures of skincare products more closely. Interest-
ingly, literature is sparse in which direct comparisons between
ECTs and ‘use tests’ were made, in particular for leave-on skincare
products (e.g. topical skin creams and lotions [6]). The original
intention of this study was to investigate to what extent single
application 24-h epicutaneous patch test results correlate with
results obtained in use tests with regard to skin compatibility of
skincare (leave-on) products. As a result of unexpected reactions in
the use test, a detour was made to modify the single application
24-h patch test protocol to address these types of reactions.
Materials and methods
Materials
The following cosmetic leave-on formulations were developed fol-
lowing the current Guidelines of Good Manufacturing Practice. Dif-
ferent preservative systems were used (noted in italics) in
accordance with Cosmetics Regulation (EC) N° 1223/2009 Annex
V.
MD70001A-3 Cream Type W/O (preservative-system: Ethyl-
paraben/Methylparaben):
Aqua, Caprylic/Capric Triglyceride, Helianthus Annuus Seed Oil,
Glycerine, Polyglyceryl-3 Polyricinoleate, Butylene Glycol, Magne-
sium Stearate, Cera Alba, Glyceryl Oleate, Cetyl Palmitate, Glyceryl
Caprylate, Magnesium Sulphate, Ethylparaben (0.4%), Methyl-
paraben (0.4%), Parfum, Sodium Pyrrolidone Carboxylic Acid.
MD70002-1 Cream Type O/W (preservative-system: preservative-
free):
Aqua, Ceteary Isononaote, Alcohol, Caprylic/Capric Triglyceride,
Dicaprylyl Ether, Cetearyl Alcohol, Glycerin, Glyceryl Stearate
Citrate, Sucrose Stearate, Ethylhexylglycerin, Parfum, Xantham
Gum, Acrylates/C10-30 Alkyl Acrylate Crosspolymer.
MD70001A Cream Type W/O (organic acid preservative-system:
Potassium Sorbate/Sodium Benzoate):
Aqua, Caprylic/Capric Triglyceride, Helianthus Annuus Seed Oil,
Glycerin, Polyglyceryl-3 Polyricinoleate, Butylene Glycol, Magne-
sium Stearate, Cera Alba, Glyceryl Oleate, Cetyl Palmitate, Glyceryl
Caprylate, Magnesium Sulphate, Potassium Sorbate (0.4%), Sodium
Benzoate (0.3%), Parfum, Sodium Pyrrolidone Carboxylic Acid,
Citric Acid.
MD70004-6 Lotion Type O/W (organic acid preservative-type sys-
tem: Potassium Sorbate/Sodium Benzoate):
Aqua, Caprylic/Capric Triglyceride, Glyceryl Stearate Citrate,
Cetearyl Alcohol, Glycerin, Glyceryl Caprylate, Sucrose Stearate,
Potassium Sorbate (0.6%), Xanthan Gum, Sodium Benzoate (0.5%),
Parfum, Carbomer.





Assessment Observed Skin Reaction
 0 No visible skin reaction
+/ 0.5 Barely perceptible or spotty erythema
+ 1/1.5* Mild erythema covering most of the test site
++ 2/2.5* Moderate erythema, possible presence of mild
oedema or a few papules
+++ 3/3.5* Marked erythema, possible extensive and
oedema or papules
++++ 4* Severe erythema, possible oedema,
vesiculation
*No further product application (Multiple EPI only).
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Methods
Ethics and general design
Prior to use, safety assessments and microbiological tests were con-
ducted to ensure the safety for human health under use conditions.
The recommendations of the current version of the Declaration of
Helsinki and the ICH Good Clinical and Research practices (GCP)
guideline were observed as applicable to a non-drug study. All vol-
unteers were informed concerning the objective, possible risks of
the study and gave their informed consent prior to initiation of the
study. The studies were performed at different single centres with
double-blind randomized product applications and under dermato-
logically controlled conditions and the supervision of a dermatolo-
gist.
Test subjects
The subjects were selected according to the following inclusion and
exclusion criteria: inclusion criteria: Caucasian female or male aged
between 18 and 76 years, volunteers being in general good health
and mental condition, and exhibiting healthy skin in the test areas.
Exclusion criteria included pregnancy or breastfeeding, known
allergies to cosmetics and cosmetic ingredients, previous adverse
reactions to materials used in the study (e.g. plasters), skin diseases
or dermatological disorders (e.g. scars, sunburn, tattoos, moles
and/or irritation) which could interfere with the evaluation of pos-
sible reactions, medication such as antibiotics or anti-inflammatory
drugs as well as the regular use of sun beds which could also affect
the skin response.
Single application epicutaneous 24-h patch test (Single EPI 24 h) and
multiple application epicutaneous patch test (Multiple EPI)
The single application epicutaneous 24-h patch test (Single EPI
24 h) and the multiple application epicutaneous patch test (Multi-
ple EPI) were conducted as a combination study. 100 µL of the test
product was applied using occlusive patches (1 cm diameter, Leu-
kotest; Beiersdorf AG, Hamburg, Germany) and affixed [Fixomull
stretch template (BSN medical, Hamburg, Germany,
15 cm 9 20 cm)]. All products were applied to the upper back,
where they remained for 24 h (day 1) and for 21 h (days 2, 3 and
4). Visual scoring was performed in accordance with a pre-defined
irritation grading scale 3 h after removal of the patches (Table 1).
Evaluations on day 1 were considered to be the Single EPI 24 h
results, whereas the sum of reactions on days 1, 2, 3 and 4 repre-
sented the Multiple EPI results. If a level 1 (or higher) reaction in
Multiple EPI had occurred, no further application of the test formu-
lation for that specific study subject was applied. All of the
equipment and instruments needed to perform the study were pre-
pared and operated by trained and experienced personnel. All
assessments were performed under normal atmospheric conditions.
Short-term in-use study (Short-term USE) and long-term in-use study
(Long-term USE)
Short-term in-use study (Short-term USE) and long-term in-use
study (Long-term USE) were conducted as a combination study
with both conducted as half-side tests. During the preconditioning
phase and during the main study, subjects were allowed to use
their personal daily cleansing products and their decorative prod-
ucts without any change in their normal regimens. Subjects were
supplied with one unit of each test product and instructed to apply
it to one side of the face twice daily as a substitute for their per-
sonal facial skincare product.
Baseline assessments were made prior to the test product appli-
cation (t0). Approx. 30 min after first application, skin reactions
were assessed (t1). These t1 reactions represent the Short-term USE
test results. However, in case of unexpected skin reactions, the
study was then terminated. After 2 weeks of specified use, possible
reactions were assessed and this time point represents the Long-
term USE results (t2). The following assessment methods were
applied: dermatological assessment of visible or tactile skin condi-
tions on each half of the face regarding erythema, oedema, dryness,
scaling, fissures, papules, pustules and vesicles. Subjective assess-
ment of skin conditions on each half of the face regarding itching,
burning, tension, tickling and dryness by the volunteer via ques-
tionnaire.
Short-term epicutaneous patch test (Short-term EPI 20 min)
For the short-term epicutaneous patch test (Short-term EPI
20 min), products were applied to the backs of approx. 30 volun-
teers with occlusive patches [Hill Top Chamber, 1 cm diameter,
exposure area: 0.79 cm2 (Hill Top Research, St. Petersberug, FL,
USA)] for 20 min. 100 µL of each test product was applied to the
patch with a pipette. Positioning of treatment locations was permu-
tated from subject to subject by means of a randomization scheme.
Visible skin reactions (e.g. erythema) were assessed by clinical scor-
ing 15 min after the removal of the patches under day light condi-
tions and applying an irritation grading scale (Table 1).
Data analysis
Data analysis was primarily based on the frequency of skin reac-
tions. A skin reaction graded as 1 or greater was considered to be
a positive reaction. Information on the skin reactions are presented
Table 2 Sex, age and skin type distribution of test subjects
Study Test subjects (n) Age Female/Male (ratio) Skin sensitivity to SDS irritation (%)
Short-term EPI 20 min
Single EPI 24 h
Multiple EPI
30 22–70 ~60%/40% ~30%
Short-term EPI 20 min
Short-term USE
(MD7001A and MD7004-6)
12 21–53 100%/0% ~41%
Short-term Use
Long-term Use
22 24–76 100%/0% ~60%
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as the number and percentage of volunteers having skin reactions.
To calculate the intensity of test reactions, the scores for all reac-
tions were summed and divided by the number of test subjects.
For the pairwise comparison of reaction rates between groups,
the Fisher’s exact test was applied on an alpha-level of 5% two-
sided to identify significant differences in rates.
Results
In an attempt to verify predictivity of results derived from closed
epicuaneous patch tests for possible irritant reactions that may
occur in open application in-use studies, three different formula-
tions MD70001A-3, MD70002-1 and MD70001A were developed.
These formulations were of different composition regarding their
ingredients and emulsion types, and in the preservative systems
used. They were developed with the initial aim of possibly having
different degrees of irritation take place. Table 2 gives an overview
of the test subjects characteristics for the different tests and formu-
lations.
Determination of the skin irritation potential in the Single EPI
24 h and Multiple EPI
In a first phase, Single EPI 24 h and Multiple EPI tests (both with
occlusive patches) were initiated in order to evaluate possible differ-
ences in irritation potentials of the formulations MD70001A-3,
MD70002-1 and MD70001A depending on the study protocol. As
depicted in Figure 1a, these three formulations did not cause any
reactions in the Single EPI 24 h, whereas differences in the irrita-
tion potential in the Multiple EPI were observed (Fig. 1b). Further-
more, 43% of the subjects developed erythema after application of
formulation MD70001A-3; the percentages of reactions for formu-
lations MD70002-1 and MD70001A were significantly lower with

























































































Figure 1 Reactions to formulations MD70001A-3, MD70002-1 and
MD70001A and are depicted [as % of volunteers reacting to the formula-
tions with objective reactions in ECTs or USE studies with an irritation level
1 (or higher) with or without subjective discomfort reactions (USE test
only)]: (a) Single EPI 24 h, (b) Multiple EPI, (c) Short-term USE and (d)
Short-term EPI 20 min.
Figure 2 Representative photograph of immediate-type skin reaction after
application of formulation MD70001A in the Short-term USE test.
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Determination of the skin compatibility in the Short-term USE test
The formulations were then tested using the Short-term USE and
Long-term USE test protocols. In these studies, products were applied
in open application under use conditions thereby more closely
resembling the use of cosmetics by the consumer. The objective of
study was to answer the question, whether differences in irritation
potentials of formulations in the epicutaneous patch test can be sub-
stantiated in the open application in-use study types (USE). The
results of Short-term USE are given in Figure 1c: Formulation
MD70001A unexpectedly induced immediate-type effects in 33% of
study subjects, which were characterized by the subjects sponta-
neously developing erythema and subjective sensations of discomfort
within 30 min after application of the test product (Fig. 2). These
reactions disappeared in the following 1–2 h. The reactivity to for-
mulation MD70001A was neither predicted by the Single EPI 24 h
nor by the Multiple EPI study results, most likely because of the
much longer time period of at least 24 h until reactions are
assessed. As a consequence of the reactions, further application of
the products for the long-term use with formulation MD70001A to
the subjects exhibiting reactions was subsequently discontinued.
Short-term EPI: Alternative to Single EPI 24 h and Multiple EPI?
To further analyze the spontaneous reaction types observed when
applying formulation MD70001A and to answer the question,
whether a modified epicutaneous patch could predict these type of
reactions, the following study type was initiated: a short-term epi-
cutaneous patch test with an application period of 20 min and
with evaluations made after 15 min (Short-term EPI 20 min). An
application period of 20 min was specifically selected, as in the
application test, reactions occured within 30 min after leave-on
product application. The formulations MD70001A-3, MD700002-1
and MD70001-A were investigated. A seemingly inverse reaction
profile in comparison to the Multiple EPI was obtained: Formula-
tions MD70001A-3 and MD70002-1 demonstrated no or only a
low number of short-term reactions, whereas formulation
MD70001-A triggered erythematous reactions in 27% of study sub-
jects (Fig. 1d). This result is in good correlation with the sponta-
neous reactions observed in the earlier open application study with
this formulation, and in which further applications were then dis-
continued. Moreover, the mean intensity scores were similar in the
Short-term EPI 20 min and Short-term USE test. The mean inten-
sity scores were 0.02 (MDF0001A-3), 0.17 (MD70002-1) and 0.41
(MD7001A) for the Short-term EPI 20 min and are 0.00
(MDF0001A-3), 0.00 (MD70002-1) and 0.60 (MD7001A) for the
Short-term USE test. However, in the Single EPI 24 h, the mean
intensity score ranges were below 0.15 (Table 3).
Table 3 Mean intensity scores after patch test removal or after short-term







MD70001A-3 0.15 0.02 0.00
MD70002-1 0.08 0.17 0.00
MD70001A 0.00 0.41 0.60

























































































Figure 3 Reactions to formulations MD70001A and MD70004-6 are
depicted as % of volunteers reacting to the formulations with objective reac-
tions in ECTs or USE studies with an irritation level 1 (or higher) with or
without subjective discomfort reactions (USE test only)]: (a) Single EPI 24 h,
(b) Multiple EPI, (c) Short-term USE and (d) Short-term EPI 20 min.
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Skin irritation results with a formulation containing a higher
concentration of the suspected urticant
To experimentally challenge the study protocols EPI 24 h and Mul-
tiple EPI and to validate the first results of the Short-term EPI 20
min as being indicative of these types of reactions, a further formu-
lation (MD70004-6) containing an even higher concentration of
the ingredients of formulation MD70001A suspected of causing the
previously described immediate reactions was developed. To this
accord, the Potassium Sorbate/Sodium Benzoate concentrations
were increased from 0.4%/0.3% (MD70001A) to 0.6%/0.5%
(MD70004-6).
As hypothesized, a higher number (100%) of study subjects
demonstrated immediate-type erythema in the Short-term EPI
20 min and 67% of the subjects developed reactions in Short-term
USE studies with formulation MD70004-6 (Fig. 3c/d). More inter-
estingly, even in the EPI 24 h, 20% of subjects and in the Multiple
EPI 60% of subjects reacted with erythema (Fig. 3a/b) indicating
that the higher concentrations may also lead to typical irritative
reactions. In addition, the mean intensity of irritant reactions was
similar in the Short-term EPI (2.46) and Short-term USE test (1.54)
compared to the Single EPI 24 h (0.40). Thus, a clear difference
between the Single EPI 24 h and Short-term USE test values was
observed (Table 3). The results show also that the intensity scores
are concentration dependent.
The reaction results for all fomulations obtained in the skin com-
patibility tests were also statistically analysed for differences using
Fisher’s exact test. Table 4 presents the results of the statistical
analysis.Since the reaction rates between Short-term EPI and
Short-term Use, were almost identical, the statistical analysis
showed a P-value of 0.8339, indicating a lack of statistically rele-
vant differences in reactions. In contrast, the generally used value
of P = 0.05 indicating statistical significance was almost achieved
(P-value of 0.0699) when comparing the Single EPI 24 h and the
Short-term EPI 20 min. The difference in the reaction rates
between Single EPI 24 h and Short-term USE is also not significant
(P = 0.1219) but a general trend in differences in reactions is
observable. Thus, the P-values support differences in reactions
between the Single EPI 24 h and the Short-term Use or Short-term
EPI 20 min. On the other hand, similar reaction rates are observed
between Short-term EPI 20 min and Short-term Use. The Multiple
EPI shows significant differences in results obtained when com-
pared to the Single EPI 24 h (P = 0.0005); when compared to the
Short-term EPI 20 min (P = 0.1134) and Short-term use test
(P = 0.1060) differences are only just not significant. The Multiple
EPI does not therefore show similar reaction rates to any of the
other three tests.
Results of epicutaneous patch test versus long-term USE
Differentiation of the irritation potentials of formulations
MD70001A-3 and MD70002-1 using the Multiple EPI was possi-
ble, but not when using the Single EPI 24 h (Fig. 3a/b). What
about their potential to cause reactions in Long-term USE studies
(Long-term USE)? The results are shown in Fig. 4. The reactions
elicited by these formulations were no cause for concern in these
types of studies, and only formulation MD70001A-3 demonstrated
reactions in 5% of study subjects. In other words, there was no
Table 4 Statistical analysis of reaction rates between the different skin com-
patibility tests
Test P-value
Single EPI 24 h Short-term USE 0.1219
Single EPI 24 h Short-term EPI 20 min 0.0699
Short-term EPI 20 min Short-term USE 0.8339
Multiple EPI Single EPI 24h 0.0005
Multiple EPI Short-term USE 0.1060
Multiple EPI Short-term EPI 20 min 0.1134






















Figure 4 Study results of Long-term USE test. Reactions to formulations
MD70001A and MD70004-6 are depicted as % of volunteers reacting to the
formulations with objective reactions with an irritation level 1 (or higher)
with or without subjective discomfort reactions.
Table 5 Summary of study results based on percentage of reactions
Formula Characteristics Short-term EPI 20 min*
Single





MD70001A-3 Cream Type W/O 0% 0% 43% 0% 5%
MD70002-1 Cream Type O/W 13% 0% 17% 0% 0%
MD70001A Cream Type W/O 27% 0% 10% 33% nt
MD70004-6 Lotion Type W/O 100% 20% 60% 67% nt
Possible concerns for further formulation development of the formulation is depicted by colour: Criteria for green (GO), orange (ATTENTION), and red (STOP) are
study type-specific considering intensity and kinetics of the reaction, data are offered as reactors in percentage, nt not tested.
*Primarily immediate-type reactions.
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clear correlation of Single EPI 24 h and Long-term USE results,
and the differences in Multiple EPI between both formulations
being on a moderate level are only minor and are mirrored by
Long-term USE study protocols.
Importance for interpretation
Table 5 offers a summary of study results with an indication the
level of concern of a study specific result that would typically influ-
ence approvals of formulations for market release. Three categories
are depicted: category green represents results with little concern,
category orange indicates the results be further verified by further
studies or alternative study protocols and, finally, category red
specifies results of high concern typically meaning a stop of the fur-
ther formulation development. Clearly, only formulations
MD70001A-3 and MD70002-1 are market-compatible, whereas
both formulations MD70001A and MD70004-6 failed but primar-
ily because of transient immediate-type effects.
Discussion
Epicutaneous patch testing (single and/or multiple application proto-
cols) is an initial in vivo method to screen for possible skin irritation
properties of a substance or formulation. Although the ECT results
in this study did not indicate substantial irritation potentials, imme-
diate-type reactions (stinging and redness) were observed in some
volunteers during the use tests which disappeared within approxi-
mately 1 h. Although transient, these reactions suggested that con-
sumer acceptance would probably be low and these studies were
discontinued. These unexpected results were nevertheless intriguing
and prompted the start of a journey to see if patch test protocols
could be modified to assess these reactions. An occlusive 20 min
short-term patch test protocol (application time based on the time
observed when reactions were observed in the short-term USE test)
with evaluations made 15 min after patch test removal was devel-
oped. It should be noted that there are parallels with the open patch
test in terms of duration of application, but the open patch test is
designed to exclude irritant reactions due to substances or formula-
tions with a potentially higher irritation potential for example for
rinse-off products which, such as household products, remain on
skin just for a short time only [5]. Successful identification of the
spontaneous reactions was possible and there was a correlation
between the intensity of reactions observed in the short-term patch
test and those observed in the controlled in-use studies.
Immediate-type reactions to cosmetic products and ingredients are
rare but have been described for some substances. Immediate-type
urticarial reactions can be categorized into two major types –
immunologic (allergic; ICoU) and non-immunologic (irritative) con-
tact urticaria (NICoU). NICoU is more prevalent than ICoU but rarely
associated with serious adverse effects and/or systemic reactions.
Although possibly not full-fledged NICoU, the induction of transient
skin redness and tingling or stinging sensations has been reported
for a number of cosmetic ingredients, for example cinnamic acid/
aldehyde, methyl salicate, dimethyl sulfoxide, nictotinic acid esters,
benzoic acid/aldehyde, sodium benzoate and potassium sorbate (non-
exhaustive) [7-9]. Vehicle effects have also been described, with
propylene glycol and isopropanol enhancing the effects of benzoic
acid reactions [7]. Coverly et al. (1998) conducted comparative stud-
ies to assess the relationship between stinging, NICoU and skin irrita-
tion [10]. A short-term type patch test was used to assess NICoU in
which the products were applied to the volar forearm for 20 min
and reactions assessed 10 min after patch removal. The substances
were applied in petrolatum. During this time, lactic acid was applied
to the nasolabial fold to assess if the volunteer is prone to develop
stinging sensations (‘stinger’). This group reported that for SDS-in-
duced irritancy and most of the tested urticants there was no differ-
ence between ‘stingers’ and ‘non-stingers’ and their propensity to
develop irritation and/or NICoU or differences in the intensity
thereof. Reactions to trans-cinnamic acid and benzoic acid were
higher in stingers. Adverse reactions to one urticant was not predic-
tive for that of other urticants. Zhai et al. (2012) initiated a study to
gain more insights into effects the anatomic region may have and
studied the elicitation of NICoU of benzoic acid and hexyl nicotinate
(HN) on the scalp, back and face of human volunteers. The back
was more sensitive to HN at low concentrations that the other two
regions, but no differences were observed at higher concentrations.
Clear cut differences in sensitivity were not observed for reactions
with benzoic acid [11,12].
As the typical symptoms of facial redness and/or the unpleasant
sensory effects are transient in that they usually appear after
10 min and disappear after 1 h, they can considerably diminish
consumer acceptance of products eliciting reactions. They may also
be involved in why consumers consider themselves to have ‘sensi-
tive skin’. These can occur although rigorous toxicological evalua-
tions and safety assessments have been conducted. As benzoates
and sorbates were used at preservatives in this study (at concentra-
tions allowed by the EU Cosmetics Regulation) and immediate-type
reactions typical of these products occurred, this was indicative of
these substances being the culprits eliciting these reactions. If
ingredients associated with immediate-type effects are used, it may
be beneficial to assess the proclivity to induce reactions early on in
product development and in particular prior to large scale con-
sumer studies. One possibility is to use the short-term patch test
protocol described in this study for formulation or substances con-
taining potential urticants.
Conclusion
Although the epicutaneous patch testing is routinely used as a
screening method in the development and optimization of cosmetic
formulations, it does not allow all reactions to be assessed and sur-
prises can be encountered. A number of ingredients can cause
spontaneous although transient reactions, such as redness possibly
indicative of reaction such as non-immunological contact urticaria.
As these reactions are transient and usually resolve within 1–2 h,
typical ECT protocols do not allow detection of immediate-type
reactions. The lessons learned from this study indicate that simple
modifications of existing test protocols can lead to important
insights into skin reactions. Subsequently, these modifications can
be used to create further building blocks leading to an optimization
of test strategies for newly developed cosmetic formulations and
finally provide reliable study designs for possible reactions. The pre-
liminary goal of this study was to investigate to what extent the
patch test results and the use test show similar results regarding
skin compatibility of skincare products. Interestingly, it resulted in
improved insights for other reactions – an unexpected journey but
this is one path science can take.
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